Summary

155 patients (including semi- and pro- athletes) with chronic tenidinopathies or tendón ruptures, non-respondent to other previous treatments, were treated with a percutaneous injection of Ex vivo culture-expanded autologous bone marrow mesenchymal stem cells, under prospective clinical essays controlled by the Spanish Drug Agency.

Abstract

Title: Results of the treatment of 144 tendinopathies and tendon ruptures with Ex vivo culture-expanded autologous bone marrow mesenchymal stem cells in clinical essays and compassionate treatment
Institution: Instituto Terapia Regenerativa Tisular, Barcelona, , SPAIN
All Authors: Rafael Arriaza-Loureda MD, PhD, Perillo, Oleiros, La Coruña, SPAIN, Presenter
Robert Soler-Rich MD, Barcelona, SPAIN
Gil Rodas MD, Barcelona, SPAIN
Lluis Orozco MD, Barcelona, SPAIN
Presenting Author: Rafael Arriaza-Loureda, MD, PhD
Presenting Author ID: 932
Summary: 155 patients (including semi- and pro- athletes) with chronic tenidinopathies or tendón ruptures, non-respondent to other previous treatments, were treated with a percutaneous injection of Ex vivo culture-expanded autologous bone marrow mesenchymal stem cells, under prospective clinical essays controlled by the Spanish Drug Agency.
Abstract: METHODS: a total of 155 patients (including semi- and pro- athletes) with chronic tenidinopathies or tendón ruptures, non-respondent to other previous treatments, were treated with a percutaneous injection of Ex vivo culture-expanded autologous bone marrow mesenchymal stem cells, under prospective clinical essays controlled by the Spanish Drug Agency. 65% of the patients were males and the median age was 49.3 years (range: 16.2 – 85.7 years). The most frequently treated tendons were patellar (41 cases), supraspinatus (40 cases), and Achilles (32 cases) ones. Average time of injury before treatment was 47 months, and all cases had received multiple treatments, including physiotherapy, PRP injections, corticoid injections, rest, eccentric exercise, or even surgery (in 16 cases).

Results

Out of the 155 cases, there is enough follow-up for 144 patients after 12 and 24 months. VAS decreased from 7.3 to 0.8 on average. For patients with Achilles tendinopathy, VAS decreased from 8.4 to 0.2. For patellar tendon patients, VAS decreased from 6.2 to 1.3. For supraspinatus patients, VAS decreased from 7.2 to 0.7. For proximal and intramuscular hamstring tendon patients, VAS decreased from 7.4 to 0.4. On average, patients required 3.5 months to return to their normal life, and athletes required 4.3 months to return to play.

Conclusions

Intratendinous injection of ex vivo culture-expanded aBM-MSC in combination with a standard rehabilitation protocol was clinically efficacious and safe in regenerating tendon in patients presenting with chronic tendinopathies and tendon ruptures. This case series suggests that intratendinous aBM-MSC therapy should be considered a promising option for the personalized treatment of chronic tendinopathies that do not respond to conventional treatments. Randomized clinical trials are warranted, in order to assess the clinical utility of aBM-MSC therapy in the treatment of chronic tendinopathies on a large clinical scale
Primary Category: Biologics
Secondary Categories: Tendon, Stem Cell Therapy
Additional Categories: MRI, Outcome Studies, Tears, Elderly, Professional Athletes / Olympians, Research
Presentation Type: Paper